FROM DEFERENCE TO EVIDENCE: ASSESSING THE PARADIGM SHIFT IN INDIAN MEDICAL NEGLIGENCE AND STEM CELL REGULATION

28 May, 2026

Share on:

I. Introduction
For nearly seven decades, the foundational bedrock of medical negligence across common law jurisdictions was governed by the doctrine of clinical deference. Articulated initially in Bolam v. Friern Hospital Management Committee

1957
1 WLR 582, this standard dictated that a medical practitioner is not negligent if they act in accordance with a practice accepted as proper by a responsible body of medical professionals. When adopted by the Supreme Court of India in Jacob Mathew v. State of Punjab (2005), the Bolam test effectively transformed professional custom into a self-validating shield. A defendant doctor merely needed to adduce peer testimony affirming similar clinical choices to foreclosing judicial scrutiny.

However, the recent landmark ruling of the Supreme Court of India in Yash Charitable Trust v. Union of India (2026) 2026 INSC 96, delivered by Justices J.B. Pardiwala and R. Mahadevan, represents a watershed transformation. By formalizing the Bolitho refinement, stringently classifying stem cell therapies under drug regulatory regimes, and anchoring informed consent within the epistemic guarantees of Article 21, the Court has transitioned Indian medical jurisprudence from an era of judicial deference to one of rigorous scientific scrutiny.

II. The Negligence Standard: Closing the Bolam Loophole via Bolitho
The structural vulnerability of the Bolam framework lay in its circularity: it anchored the standard of care in peer practice rather than empirical science. English law sought to limit this insularity in Bolitho v. City & Hackney Health Authority

1998
AC 232, wherein Lord Browne-Wilkinson held that a medical opinion, to be legally "responsible," must be capable of withstanding logical analysis and balancing comparative risks against benefits.
In Yash Charitable Trust, this distinction became the central focal point. The case emerged from a writ petition challenging commercial clinics offering unapproved stem cell therapies for Autism Spectrum Disorder (ASD). The clinics contended that because numerous practitioners offered identical treatments, their collective consensus formed a "responsible body of opinion."

Rejecting this defense, the Supreme Court integrated the Bolitho refinement into mainstream Indian law. The Court established that a convergence of professional practice is legally irrelevant if it lacks an evidential foundation in established science. Furthermore, the bench innovatively invoked Article 51A(h) of the Constitution—the Fundamental Duty to cultivate a scientific temper—juxtaposed against the Article 21 right to health, creating a constitutional mandate for clinical epistemology. Custom can no longer substitute for empirical verification.

III. Statutory Classification: Closing the "Procedure" Escape Route
To evade the strict licensing and clinical trial mandates of the Central Drugs Standard Control Organisation (CDSCO), commercial operators routinely characterized stem cell interventions as localized medical "procedures" or "treatment protocols" rather than pharmaceutical administrations.

The Supreme Court dismantled this semantic loophole by enforcing a literal and teleological interpretation of the Drugs and Cosmetics Act, 1940. Under Section 3(b) of the Act, alongside Rule 2(zd) of the New Drugs and Clinical Trials (NDCT) Rules, 2019, any biological substance—including cell-based products—that has not previously been approved for a specific indication is legally classified as a "New Drug." By aligning judicial interpretation with the ICMR-DBT Guidelines for Stem Cell Research and Therapy (2017), the Court distinguished between minimally manipulated cells for homologous use (permissible procedures) and substantially manipulated cells for non-homologous indications (drugs). This classification yields three severe legal consequences:

1. Commercial administration of unapproved stem cell therapies constitutes a criminal offense under Section 27 of the Drugs and Cosmetics Act.
2. Administering clinics are strictly bound by statutory pharmacovigilance and adverse event-reporting mandates.
3. The doctrine of "consented unlicensed use" is entirely invalidated; because regulatory licensing is a substantive public policy precondition, a patient cannot legally contract out of statutory protections to validate an unlicensed drug.

IV. Informed Consent: The Epistemic Dimension of Article 21
Indian jurisprudence on informed consent, historically anchored in Samira Kohli v. Dr. Prabha Manchanda (2008), primarily regulated procedural disclosure—ensuring patients were informed of known risks, alternatives, and physical side effects.

Yash Charitable Trust addresses an entirely distinct informational pathology: an epistemic defect. The infraction by commercial clinics was not the concealment of known risks, but the active misrepresentation of an experimental, unproven therapy as an established, scientifically validated cure.

The Court held that autonomous decision-making, protected under the Article 21 right to life and personal liberty, is completely subverted when a patient’s choice is leveraged on an entirely false evidential premise. Consequently, the Court declared such consent null and void ab initio. Where a practitioner misrepresents the scientific status of a therapy to secure consent, the traditional consent-based defense against civil and professional negligence liability collapses. The Court explicitly recognized the severe institutional informational asymmetry and caregiving desperation of families, refusing to treat these transactions as arm's-length agreements.

V. The National Medical Commission (NMC) Advisory: Institutional Enforcement
To operationalize these principles, the National Medical Commission issued a binding Advisory establishing a rigid two-track regulatory framework:

• The Approved Track: Validated stem cell therapies for recognized haematopoietic conditions (e.g., thalassaemia major, leukaemia) remain permissible under standard clinical oversight.
• The Experimental Track: Unapproved indications, including ASD, are strictly prohibited from commercial exploitation and restricted exclusively to registered clinical trials under the NDCT Rules, subject to four non-negotiable mandates:

1. Absolute prohibition on charging patients or subjects.
2. Mandatory registration with the Clinical Trials Registry-India (CTRI).
3. Strict prohibition on financial inducement to participants.
4. Provision of no-fault compensation for trial-related injuries, moving the tortious burden from proof of negligence to a strict liability framework aligned with the Declaration of Helsinki.

VI. Conclusion
Yash Charitable Trust v. Union of India marks a structural evolution in Indian medical law. By neutralizing the circular immunity of the Bolam test, establishing the statutory identity of advanced cell therapies as drugs, and elevating informed consent to an evidence-based constitutional guarantee, the Supreme Court has built a formidable regulatory bulwark. This framework successfully balances the demands of genuine biomedical innovation with the absolute necessity of protecting vulnerable patients from predatory commercial exploitation.